TipRanks
Advertisement
Advertisement
Immix Biopharma reports promising interim Phase 2 results
PremiumCompany AnnouncementsImmix Biopharma reports promising interim Phase 2 results
23d ago
Immix announces 89% CR rate in interim update across NEXICART-2 patients
Premium
The Fly
Immix announces 89% CR rate in interim update across NEXICART-2 patients
23d ago
Immix Biopharma prices 11.36M share registered offering at $11.00
Premium
The Fly
Immix Biopharma prices 11.36M share registered offering at $11.00
23d ago
Immix Biopharma initiated with a Buy at Needham
PremiumThe FlyImmix Biopharma initiated with a Buy at Needham
3M ago
Midday Fly By: Domino’s reports mixed Q2, Tempus AI to acquire Personalis
Premium
The Fly
Midday Fly By: Domino’s reports mixed Q2, Tempus AI to acquire Personalis
3M ago
Immix Biopharma announces termination of CMO Richard Graydon
Premium
The Fly
Immix Biopharma announces termination of CMO Richard Graydon
3M ago
Immix Biopharma Shareholders Back Board and Auditor at AGM
PremiumCompany AnnouncementsImmix Biopharma Shareholders Back Board and Auditor at AGM
5M ago
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright
Premium
The Fly
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright
5M ago
Immix Biopharma Raises $150 Million to Advance NXC-201
Premium
Company Announcements
Immix Biopharma Raises $150 Million to Advance NXC-201
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―